Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
View the latest research on other companies in the sector.
Good organic growth but weak margins in Q4. 2024 will be a year of transition. EBITDA revised down 8-11% for '24e-'25e.
PBD PBP PBYA PBX PROB PROB PBYA
51% beat on EBITDA in Q3. New strategy and mid-term financial targets. Earnings revised up for '23e, but down for '24e-'25e.
Weak orders in Americas and EMEA plus high COGS/SG&A costs hurt profitability. Share trading at NTM EV/EBITA of 28x-12x for '23-'25.
PBD PBP PBX PROB PBYA 0GZB
Share: